Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

Figure 3

Comparison of overall survival after cervical cancer recurrence between vaccinated patients and a matched cohort of non-vaccinated cervical cancer patients. The survival of the group of 16 vaccinated patients with a cervical carcinoma was compared to a cohort group of non-vaccinated patients who where primarily matched for FIGO stage, time to recurrence, primary treatment and salvage therapy after recurrence and which turned out to be matched also for age of diagnosis, age of recurrence, the type of primary and salvage chemotherapy as well as for adjuvant therapy. Both the log-rank and the Wilcoxon signed rank test revealed no difference in survival between the two groups.

Back to article page